YCT-529 blocks vitamin A metabolite to prevent sperm production without hormones Phase 1 trial on 16 vasectomised men showed YCT-529 was well-tolerated with no serious side effects Optimal dosage estimated at 180 mg; efficacy in sperm reduction still under study in phase 2 trials